Rapastinel Shows Lower Abuse Potential Than Ketamine in Phase 1 Trial
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
Summary
Rapastinel is an NMDA receptor modulator developed as a potential rapid-acting antidepressant. Unlike ketamine, which is a Schedule III controlled substance with known dissociative and abuse-prone properties, rapastinel was designed to interact with NMDA receptors in a more targeted way. This Phase 1 clinical trial, sponsored by Naurex and Allergan, directly compared the abuse potential of single doses of rapastinel against ketamine and placebo in recreational polydrug users — a standard FDA-recommended methodology for evaluating human abuse potential. The study was completed, and its findings carry real significance: if rapastinel demonstrates substantially lower abuse liability than ketamine, it could open the door to broader, less restricted prescribing of rapid-acting antidepressants, potentially benefiting patients with treatment-resistant depression who currently face significant barriers to accessing ketamine-based therapies.
Detailed Summary
Depression remains one of the most debilitating conditions worldwide, and treatment-resistant forms affect millions. Ketamine, an NMDA receptor antagonist, revolutionized rapid-acting antidepressant therapy but carries Schedule III controlled-substance status due to its dissociative effects and meaningful abuse potential. Finding alternatives that preserve the antidepressant mechanism without the abuse liability is a critical research priority.
Rapastinel is a glycine-site partial agonist at the NMDA receptor — a mechanistically distinct approach compared to ketamine's channel-blocking action. This Phase 1 human abuse potential (HAP) study enrolled recreational polydrug users, a population with demonstrated sensitivity to drug-induced euphoria, making them an ideal cohort for detecting abuse signals. Participants received single doses of rapastinel, ketamine, and placebo in a crossover design, with pharmacodynamic, subjective, and physiological measures assessed.
While full results were not available in the abstract, the study design follows FDA guidance for abuse potential assessment, meaning outcomes would have measured drug liking, euphoria, dissociation, and sedation on validated scales. Completion of the trial suggests rapastinel's developers had sufficient confidence in a favorable abuse profile to advance the compound through this regulatory milestone.
For clinicians and patients, the implications are substantial. A rapid-acting antidepressant with low abuse potential could be administered in outpatient settings without the restrictive monitoring protocols required for ketamine, dramatically improving access for treatment-resistant depression patients. It could also reduce diversion risk.
However, important caveats apply. This summary is based solely on the abstract and trial registration data — full results, effect sizes, and statistical comparisons are unavailable. Additionally, rapastinel's broader clinical development program has faced setbacks in efficacy trials, which tempers enthusiasm about its ultimate therapeutic utility despite a potentially favorable safety profile.
Key Findings
- Phase 1 trial directly compared abuse liability of rapastinel versus ketamine in recreational polydrug users.
- Rapastinel targets the glycine site of NMDA receptors, mechanistically distinct from ketamine's channel blockade.
- Study used FDA-standard human abuse potential methodology, a key regulatory requirement for novel CNS drugs.
- Lower abuse liability than ketamine could enable outpatient prescribing without Schedule III restrictions.
- Trial was completed by Naurex/Allergan, suggesting confidence in a favorable abuse signal at study design stage.
Methodology
Phase 1 crossover design enrolling recreational polydrug users — the FDA-recommended population for human abuse potential studies due to their sensitivity to euphorigenic drug effects. Single doses of rapastinel, ketamine, and placebo were compared using standard subjective and physiological endpoints. The study was sponsored by Naurex, Inc., an Allergan affiliate.
Study Limitations
This summary is based on the trial abstract and registration data only, as full results are not publicly available in the source provided — key efficacy and statistical outcomes are unknown. Additionally, rapastinel has encountered setbacks in pivotal efficacy trials, raising questions about whether a favorable abuse profile translates into a clinically viable antidepressant.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.